Good morning :)
$
₹
P

Pluri Inc.

PLUR

NASDAQ
P

Pluri Inc.

PLUR

NASDAQ
$1.078.78% (+0.08)
$
₹
$1.078.78% (+0.08)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $12.5M the stock is ranked 5615

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

306.55
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.39
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on consolidated analysts reports

?

Buy, Sell and Hold recommendations are not available

Price Upside

+1112.12%

Earnings Growth

-59.66%

Rev. Growth

+902.46%

See Detailed Forecast

Company Profile

Company Profile

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform. Its product candidates include PLX-PAD, which is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, as well as contract development and manufacturing organization (CDMO) services for pharmaceutical and biotechnology companies under the PluriCDMO division, and AgTech. It has a collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform. Its product candidates include PLX-PAD, which is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, as well as contract development and manufacturing organization (CDMO) services for pharmaceutical and biotechnology companies under the PluriCDMO division, and AgTech. It has a collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.68
80.68
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.28
27.28
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.90
29.90
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 1112.12% growth, versus a trailing 3-year CAGR of -35.79%.

2026
Current$0.99Baseline
Analyst Target - 1 year
Target$12+1112.12%

All values in $

202220232024202520262027$3.97$7.05$10.12Target+1112.12%
2026
Current$0.99Baseline
Analyst Target - 1 year
Target$12+1112.12%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 902.46% growth, versus a trailing 3-year CAGR of 52.41%.

2026
Current$1.01Baseline
Forecast for Jun 2027
High$10.18+902.46%
Average$10.18+902.46%
Low$10.18+902.46%

All values in $ Million

2022202320242025202620270.230.280.321.331.01Low+902.46%Average+902.46%High+902.46%
2026
Current$1.01Baseline
Forecast for Jun 2027
High$10.18+902.46%
Average$10.18+902.46%
Low$10.18+902.46%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2026
Current$-1.19Baseline
Forecast for Jun 2027
High$-1.9-59.66%
Average$-1.9-59.66%
Low$-1.9-59.66%

All values in $

202220232024202520262027-8.36-3.79-2.38-3.55-1.19Low-59.66%Average-59.66%High-59.66%
2026
Current$-1.19Baseline
Forecast for Jun 2027
High$-1.9-59.66%
Average$-1.9-59.66%
Low$-1.9-59.66%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

0.3
-5.8
0.1
-6.5
0.1
-6.1
0.3
-5.8
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.070.090.320.180.420.390.310.190.160.33
Net Income-5.29-5.72-5.88-2.95-6.14-7.59-5.85-6.54-6.17-5.88
Net Profit Margin-7454.92%-5967.70%-1804.29%-1597.83%-1439.57%-1909.04%-1851.26%-3304.54%-3695.80%-1755.22%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Pluri Inc. -306.55-
AbbVie Inc80.6850.450.53
Amgen Inc27.2817.562.28
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare PLUR with any stock or ETF
Compare PLUR with any stock or ETF
Comparing from
PLUR
ABBV
AMGN
Loading...

Frequently asked questions

  1. Pluri Inc. (PLUR) share price today is $1.07 as of October 27, 2026 at 12:16 AM IST. The stock touched a day high of $1.33 and a day low of $1.04.

  2. Pluri Inc. stock trades on NASDAQ under the ticker symbol PLUR.

  3. Pluri Inc.'s market capitalization is $12.48M as of October 27, 2026 at 12:16 AM IST.

  4. Pluri Inc.'s price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Pluri Inc.'s price-to-book (P/B) ratio is 306.55 as of October 26, 2026.

  6. Yes, You can buy Pluri Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Pluri Inc. shares in three steps: 1. Search Pluri Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Pluri Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Pluri Inc. (PLUR) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 9.285 shares at the current price of $1.07.

Loading...